13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001816307
Total reported value
$962.2M
$962.2M
77 檔
9.2%
The Q1 2024 SEC filing reveals that Silverarc Capital Management, LLC held a total portfolio value of $962.2M, covering 77 public equity positions.
During Q1 2024, Silverarc Capital Management, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ✓ | Merus N V | Stock-Other | 7.08% | — | -12.28% | |
| 2 | SLDB | Solid Biosciences Inc | Stock-Other | 4.90% | +0.69% | NEW | |
| 3 | MORFUSD | Morphic Holding Inc | Stock-Other | 4.73% | — | -3.21% | |
| 4 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 4.25% | -0.59% | -4.87% | |
| 5 | ✓ | Mersana Therapeutics Inc | Stock-Other | 3.69% | — | -55.83% | |
| 6 | CLDX | Celldex Therapeutics Inc | Stock-Other | 3.49% | -0.58% | EXIT | |
| 7 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 3.47% | — | — | |
| 8 | NUVL | Nuvalent Inc-a | Stock-Other | 3.29% | -3.71% | EXIT | |
| 9 | CCCC | C4 Therapeutics Inc | Stock-Other | 3.26% | +0.96% | — | |
| 10 | PRAX | Praxis Precision Medicines I | Stock-Other | 3.23% | -0.06% | -32.87% | |
| 11 | PSTXUSD | Poseida Therapeutics Inc | Stock-Other | 3.19% | — | -2.95% | |
| 12 | AKRO | Akero Therapeutics Inc | Stock-Other | 2.81% | — | +60.46% | |
| 13 | ISREUR | Isoray Inc | Stock-Other | 2.68% | — | — | |
| 14 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 2.21% | +0.87% | +5.47% | |
| 15 | NVLSEUR | Alpine Immune Sciences Inc | Stock-Other | 2.19% | — | -33.17% | |
| 16 | URGN | UroGen Pharma Ltd. | Stock-Other | 2.12% | +2.22% | -3.20% | |
| 17 | GOSS | Gossamer Bio Inc | Stock-Other | 2.01% | — | — | |
| 18 | MGNX | Macrogenics Inc | Stock-Other | 1.95% | — | -62.02% | |
| 19 | COGT | Cogent Biosciences Inc | Stock-Other | 1.93% | -0.01% | +7.23% | |
| 20 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 1.85% | -5.91% | EXIT | |
| 21 | KOD | Kodiak Sciences Inc | Stock-Other | 1.81% | -1.65% | +23.88% | |
| 22 | VCYT | Veracyte Inc | Stock-Other | 1.73% | +1.35% | +13.34% | |
| 23 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 1.66% | — | — | |
| 24 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 1.62% | — | -10.20% | |
| 25 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 1.44% | — | — | |
| 26 | EYPT | Eyepoint Inc | Stock-Other | 1.42% | — | — | |
| 27 | BOLD | Boundless Bio Inc | Stock-Other | 1.24% | — | — | |
| 28 | TELA | Tela Bio Inc | Stock-Other | 1.22% | +0.03% | -2.29% | |
| 29 | BIIB | Biogen Inc | Stock-Healthcare | 1.16% | +0.13% | -3.17% | |
| 30 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 1.04% | -0.33% | EXIT | |
| 31 | SRRK | Scholar Rock Holding CORP | Stock-Other | 0.98% | -1.70% | EXIT | |
| 32 | CYTK | Cytokinetics Inc | Stock-Healthcare | 0.97% | -0.48% | EXIT | |
| 33 | APGE | Apogee Therapeutics Inc | Stock-Other | 0.92% | — | — | |
| 34 | JSPR | Jasper Therapeutics Inc | Stock-Other | 0.90% | — | — | |
| 35 | INSM | Insmed Inc | Stock-Healthcare | 0.86% | -0.22% | -26.94% | |
| 36 | WVE | Wave Life Sciences Ltd. | Stock-Other | 0.85% | — | — | |
| 37 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.81% | +0.69% | -2.27% | |
| 38 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.79% | — | -59.50% | |
| 39 | DXCM | Dexcom Inc | Stock-Healthcare | 0.77% | — | -35.48% | |
| 40 | CERS | Cerus CORP | Stock-Other | 0.77% | +0.46% | -2.27% | |
| 41 | PLRX | Pliant Therapeutics Inc | Stock-Other | 0.76% | — | -42.42% | |
| 42 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 0.76% | — | -73.61% | |
| 43 | ✓ | Compugen LTD | Stock-Other | 0.72% | -0.01% | +6.38% | |
| 44 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 0.67% | — | -56.49% | |
| 45 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 0.65% | — | — | |
| 46 | ✓ | Evogene LTD | Stock-Other | 0.64% | — | -0.47% | |
| 47 | ✓ | Adc Therapeutics SA | Stock-Other | 0.63% | — | — | |
| 48 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 0.61% | — | — | |
| 49 | ✓ | Macrogenics Inc | Stock-Other | 0.59% | — | — | |
| 50 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 0.55% | — | -2.00% |
According to official SEC Form 13F filings, Silverarc Capital Management, LLC reported a total U.S. public equity portfolio value of $962.2M across 77 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including MERUS N V, SLDB, MORFUSD) accounted for 9.2% of total reported equity market value during Q1 2024.
During Q1 2024, Silverarc Capital Management, LLC's top holdings by market value included MERUS N V (7.1%)、SLDB (4.9%)、MORFUSD (4.7%). The largest single position, MERUS N V, represented 7.1% of total portfolio value.
In Q1 2024, Silverarc Capital Management, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.